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S U M M A R Y
Background: The recommended standard therapeutic regimen for chronic hepatitis patients with
hepatitis C virus (HCV) genotype 3 is pegylated interferon plus ribavirin for 24 weeks. The aim of the
present study was to evaluate treatment efﬁcacy and variables predictive of treatment success,
interactions among variables contributing to a response to therapy, and the utility of the rapid virological
response (RVR; week 4 virological response) to predict treatment outcomes in HCV genotype 3-infected
patients in routine clinical practice.
Methods: We prospectively studied baseline and during-treatment factors associated with a sustained
virological response (SVR) in HCV genotype 3-infected patients who received pegylated interferon alfa-
2a (PEG-IFN a2a) 180 mg/week plus ribavirin 800 mg daily for 24 weeks and who were followed for 24
weeks after the completion of treatment.
Results: Four hundred and twenty-six treated patients were included in the analysis; 320 (75.1%)
showed an SVR. The following factors were assessed for their ability to predict SVR by means of
univariable and multivariable logistic regression analysis: patient age, sex, pre-treatment viral load, pre-
treatment alanine aminotransferase (ALT), body mass index (BMI), and RVR. Four factors – age, pre-
treatment viral load, pre-treatment ALT, and RVR – were statistically signiﬁcant predictors of SVR
(p < 0.05) in the univariable analysis. Factors showing a signiﬁcant association with SVR were assessed
by multivariable logistic regression analysis. In the multivariable analysis, independent factors
associated with SVR were the attainment of RVR (odds ratio (OR) 11, 95% conﬁdence interval (CI) 6.15–
20.69; p < 0.0001), patient age 40 years (OR 4.2, 95% CI 2.30–7.96, p < 0.0001), and a low pre-treatment
viral load (8  105 IU/ml; OR 3.4, 95% CI 1.87–6.25; p < 0.0001). The effect of RVR in patients aged >40
years was more pronounced than in those aged 40 years: 81.1% of patients aged >40 years who
achieved an RVR had an SVR, whereas only 7.5% of patients aged >40 years who did not achieve an RVR
had an SVR (p < 0.05).
Conclusions: RVR is an independent variable that is predictive of SVR. Moreover older patients (>40
years) who achieve an RVR are likely to have an SVR, while patients who do not achieve an RVR and who
have a high pre-treatment viral load (>8  105 IU/ml) are unlikely to have an SVR.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis C virus (HCV) represents a major public health issue
across the world in general, and particularly in Pakistan. Around
200 million people are infected with HCV worldwide – approxi-
mately 3.3% of the world’s population.1,2 In Asian-Paciﬁc regions,
the prevalence of HCV infection ranges from 0.3% to 12%,3 and in* Corresponding author. Tel.: +92 3 004852451.
E-mail address: hafsa.aziz@gmail.com (H. Aziz).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.03.012Pakistan, 5.9% of the population (>10 million individuals) are
living with HCV, with high morbidity and mortality.4
Chronic hepatitis C is associated with an increased risk of the
development of liver cirrhosis and its progression to hepatocellular
carcinoma.5,6 Due to the lack of a protective vaccine, successful
treatment of this infection is of the utmost importance. The main
treatment goal in chronic hepatitis C is to eradicate the virus or, in
purely clinical terms, to attain a sustained virological response
(SVR), deﬁned as an undetectable serum HCV RNA level at 6
months after the end of treatment.7 Moreover, the response to
therapy is related to the HCV genotype. In Pakistan genotype 3 isses. Published by Elsevier Ltd. All rights reserved.
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rare.8 Treatment with pegylated interferon (peginterferon; PEG-
IFN) plus ribavirin is currently the standard of care for eradicating
the virus in chronic HCV patients, with an SVR rate of 80% in
patients with genotype 2 and 3 infections.9 However only a few
studies have been undertaken to predict the response rate to PEG-
IFN alfa plus ribavirin treatment in Pakistani populations, which
have shown response rates lower than those previously published
in Western populations in easy-to-treat groups.10–12
PEG-IFN plus ribavirin treatment is not common in Pakistan
because this drug regimen is expensive. Considering the costs of
treatment and the adverse effects of therapy, a prediction of the
response to antiviral treatment is very important. Previous studies
have not explored the usefulness of positive and negative
predictors of SVR in HCV genotype 3 patients treated with a
standard dose of PEG-IFN 180 mg/week subcutaneously and
ribavirin 800 mg daily for 24 weeks. Thus, the aim of this study
was to investigate whether early changes at week 4 in HCV RNA
levels during treatment with PEG-IFN alfa-2a (PEG-IFN a2a) and
ribavirin (i.e., rapid virological response (RVR) deﬁned as HCV RNA
negative at 4 weeks after treatment initiation) could be used as a
predictor of SVR in HCV patients.
2. Patients and methods
2.1. Patient selection
Adult patients aged 18 years, both male and female, infected
with HCV genotype 3, who had elevated serum alanine amino-
transferase (ALT) levels (deﬁned as 1.2 times the upper limit of the
normal range) on two occasions during the 6 months prior to entry
into the study, were positive for anti-HCV antibodies, and who had
a positive polymerase chain reaction for HCV RNA, were eligible for
inclusion. Other eligibility criteria included a hemoglobin concen-
tration >13 g/dl in men or >12 g/dl in women, white blood cell
count >3  109/l, platelet count >100  109/l, normal serum
bilirubin and albumin, and normal thyroid function tests. Patients
were excluded if they were suffering from decompensated liver
disease, autoimmune disorders, or had a history of depression orTable 1
Baseline characteristics of 426 patients infected with HCV
Characteristic Number of patients %
Sex
Male 209 49.1
Female 217 50.9
Age, years
40 219 51.4
>40 207 48.6
Source of infection
Blood transfusion 26 6.1
Dentist treatment 134 31.5
Surgery 35 8.2
Surgery + transfusion 29 6.8
Unknown source 202 47.4
Viral load
8  105 IU/ml 203 47.7
>8  105 IU/ml 223 52.3
ALT
Normal ALTa 76 17.8
Raised ALTb 350 82.2
BMI
27 kg/m2 282 66.2
>27 kg/m2 144 33.8
HCV, hepatitis C virus; ALT, alanine aminotransferase; BMI, body mass index.
a Normal ALT group: patients who have serum alanine aminotransferase below
the upper limit of the normal range, i.e., male <41, female <31.
b Raised ALT: patients who have serum alanine aminotransferase equal to or
above the upper limit of the normal range, i.e., male 41 U/l, female 31.cardiac diseases. Patients aged <18 years or >70 years, pregnant
women, and those positive for hepatitis B surface antigen were also
excluded from the study. Baseline characteristics of the study
patients are shown in Table 1.
2.2. Study design
This prospective study was conducted at the Islamabad
Specialist Clinic in Islamabad from June 2010 through August
2011. This study was approved by the ethics committee of the
clinic, and informed written consent was obtained from all of the
patients who participated. A ﬂow diagram showing patient
enrolment and progression through the study is shown in Figure 1.
Data was collected from all patients by the Digestive Disease
Study Group at the Islamabad Specialist Clinic. Eligible patients
received PEG-IFN a2a (Pegasys) at the standard dose of 180 mg/
week subcutaneously and ribavirin 800 mg daily for 24 weeks. The
data analysis was performed by the authors of this report. Routine
laboratory testing (prothrombin time and complete blood count)
was analyzed after 4 weeks, and thyroid-stimulating hormone
(TSH; for thyroid function) was assessed at 12 weeks of therapy
and at 24 weeks following the completion of therapy. RVR was
assessed after 4 weeks of therapy (on the basis of quantitative HCV
PCR). Patients who achieved RVR were reassessed after completion
of therapy. Patients who had detectable HCV RNA or who showed a
less than 100-fold drop in viral load from baseline at 12 weeks of
therapy were considered non-responders and ceased further
treatment and follow-up. Only responder patients were followed
up after the completion of therapy for the determination of SVR;
the follow-up period was 24 weeks.
Adverse events were also recorded throughout the study for all
patients who underwent therapy. All of the patients attended for
monthly visits during the treatment period and during the 24-
week follow-up period.
2.3. Viral assessments and endpoint
Serum levels of HCV indicate the level of HCV replication within
the infected individual. The commercially available Rotor-Gene
quantitative real-time PCR (RT-PCR) assay (Qiagen) was used to
assess the virological status at baseline and at treatment weeks 4
and 12. An HCV RNA qualitative test was performed in responders
to detect the end of treatment response (ETR) and SVR at 24 weeks
after the completion of treatment. Genotyping of HCV was
performed using the Invader HCV Genotyping Assay (Third Wave
Technologies, Inc.).13
The primary endpoint of this study was the assessment of SVR,
which was deﬁned as the absence of detectable HCV RNA at 6
months after the completion of treatment. Non-responders were
those with detectable HCV RNA or who showed a less than 100-
fold drop in viral load from baseline at 12 week of therapy.
Secondary endpoints were the variables associated with SVR,
interactions among variables contributing to the response to
therapy, and the utility of the virological response at week 4 (RVR;
undetectable HCV RNA at 4 weeks of treatment) in the prediction
of treatment outcome in HCV-infected patients.
2.4. Statistical analysis
The analysis was based on the 426 patients who completed
treatment. Analyses were carried out using SPSS v. 15.0 (SPSS Inc.,
Chicago, IL, USA). Categorical variables are given as the number and
percentage. Pearson’s Chi-square test was used to evaluate the
associations of variables with the likelihood of achieving SVR. A p-
value lower than 0.05 was considered signiﬁcant. A multivariable
logistic regression analysis was performed to explore the
454 patients enrolled for PEG-IFN 2a and  
ribavirin
Patients who did not have RVR 
(n = 108)
Patients who had 
SVR
(n = 272)
470 patients assessed for eligibility
Excluded (n = 16) 
Failed to meet inclusion 
criteria
Excluded (n = 28) 
Refused to participate 
Patients who had 
no SVR 
(n = 4 6)
No SVR
(n=14 )
Yes SVR
(n=48)
426 patients received PEG-IFN 2a and
ribavirin
Patients who had RVR 
(n = 318)
Patients who had EVR 
(n = 62)
Patients who did not have EVR 
(n = 46)
Non-responder 
(n = 46)
Figure 1. Flow diagram of the study, showing virological response rates during the treatment and follow-up periods. A total of 454 subjects fulﬁlled the inclusion criteria and
were assigned to treatment. Twenty-eight patients were excluded after receiving one or two doses because they refused to continue therapy or did not come for treatment
(PEG-IFN a2a, pegylated interferon alfa-2a; SVR, sustained virological response; RVR, rapid virological response (undetectable HCV RNA at week 4); EVR, early virological
response (at week 12)).
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signiﬁcantly associated with SVR by univariable analysis were
entered into a multivariable model. The following variables were
considered: sex, age, pre-treatment ALT, pre-treatment HCV RNA
levels, RVR, and body mass index (BMI).
3. Results
3.1. Patient demographic and other baseline characteristics
Patient disposition and the response to treatment is shown in
Figure 1. Four hundred and seventy Pakistani HCV patients who
were treatment-naı¨ve or who had previously been treated with
conventional interferon plus ribavirin combination therapy were
assessed for study enrolment. Patients infected with HCV
genotypes other than genotype 3 were excluded. A ﬁnal total of
426 chronic HCV patients satisfying the study criteria were
included in this study. Of the 426 patients, 209 were males and 217
were females. The baseline characteristics of the patients are
summarized in Table 1. Surgery and dental treatment were the
main modes of acquisition of the HCV infection.
3.2. Virological response
At the completion of treatment, viral clearance was achieved in
380/426 (89.2%) subjects. SVR (i.e., no detectable HCV RNA at 24
weeks after completion of therapy) was achieved in 320/426
(75.1%) subjects. Forty-six patients (10.8%) were virological non-
responders, showing detectable HCV RNA at week 12 of therapy(Figure 1). All patients who achieved an undetectable HCV RNA at 4
weeks (RVR) were HCV RNA-negative at the end of treatment.
The rate of SVR was higher in patients aged 40 years as
compared to patients aged >40 years (80.8% vs. 69.1%; p = 0.005).
Viral load at baseline was found to vary widely among the infected
patients; ﬂuctuations in viral load are known to occur in patients
with chronic hepatitis C. For the purpose of the analysis, viral load
was categorized into two levels: low at 8  105 IU/ml and high at
>8  105 IU/ml. The response to PEG-IFN therapy was associated
with the viral load; patients with a pre-treatment viral load of 8 
105 IU/ml responded better to therapy than those with a viral load
of >8  105 IU/ml (87.7% vs. 63.7%; p < 0.0001).
3.3. Rapid virological response
We examined the signiﬁcance of RVR as a predictor of SVR.
Three hundred and eighteen patients (74.6%) achieved an RVR to
treatment and among these 272 (85.5%) achieved an SVR while 46
(14.5%) patients did not achieve an SVR. In the group of patients
who did not achieve an RVR, an SVR was achieved in 48 (44.4%).
The SVR rate was signiﬁcantly higher in patients who had an RVR
as compared to those who did not have an RVR (85.5% vs. 44.4%;
p < 0.0001) (Table 2).
The cumulative effect of HCV RNA level and RVR to SVR was also
analyzed. SVR to PEG-IFN was 79.9% in patients with a high viral
load (>8  105 IU/ml) and RVR, while the SVR was 18.6% in patients
with a high viral load who did not achieve RVR (p < 0.05). The
effect of RVR in patients aged >40 years was more pronounced
than in those aged 40 years: 81.1% of patients who achieved RVR
Table 2
Variables associated with SVR in HCV patients treated with PEG-IFN a2a plus
ribavirin therapy
Variable Total number
of treated
patients
Achieved
SVR
SVR
rate %
p-Value
Age, years 0.005
40 219 177 80.8%
>40 207 143 69.1%
Sex 0.11
Male 209 164 78.5%
Female 217 156 71.9%
Pre-treatment viral load <0.0001
8  105 IU/ml 203 178 87.7%
>8  105 IU/ml 223 142 63.7%
Response rate at week 4 <0.0001
RVR 318 272 85.5%
Non-RVR 108 48 44.4%
Pre-treatment ALT 0.02
Normal ALT 76 65 85.5%
Raised ALT 350 255 72.9%
BMI 0.14
27 kg/m2 282 218 77.3%
>27 kg/m2 144 102 70.8%
Figure 2. Rate of SVR in HCV-infected patients by age and RVR (SVR, sustained
virological response; RVR, rapid virological response (undetectable HCV RNA at
week 4); NRVR, patients who did not have RVR).
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patients who did not achieve RVR and who were aged >40 years
had an SVR (p < 0.05) (Figure 2).
3.4. Biochemical response
Study subjects were classiﬁed into two groups on the basis of
ALT levels at the time of treatment: a raised ALT group (male 41
U/l, female 31 U/l) and a normal ALT group (male <41 U/l, female
<31 U/l). Overall 76 patients (17.8%) had normal serum ALT. Serum
ALT decreased to normal levels after treatment completion in 336
(96%) patients in the raised ALT group. SVR was present in 65
(85.5%) patients in the normal ALT group and in 255 (72.9%) in the
raised ALT group (Table 2).
3.5. Predictors of a sustained virological response to PEG IFN a2a
Factors entered into the univariable logistic regression analysis
were sex, age, pre-treatment viral load, BMI, pre-treatment ALT
level, and RVR at week 4. By univariable logistic regression analysis
we found that the efﬁcacy of PEG-IFN for SVR depends upon:
baseline HCV RNA level 8  105 IU/ml (odds ratio (OR) 4.0, 95%
conﬁdence interval (CI) 2.46–6.69; p < 0.0001), age 40 years (OR
4.1, 95% CI 2.5–6.7; p = 0.005), ALT below the upper limit of normal
(OR 2.2, 95% CI 1.11–4.34; p = 0.02), and achieving RVR (OR 7.3, 95%
CI 4.52–12.08; p < 0.0001) (Table 3).Table 3
Univariable and multivariable logistic regression analysis of treatment and baseline ch
Variable Sustained virological resp
Univariable analysis 
OR (95% CI) 
Sex (female vs. male) 0.7 (0.45–1.09) 
Age, years (40 vs. >40) 4.1 (2.5–6.7) 
BMI, kg/m2 (27 vs. >27) 0.7 (0.45–1.12) 
ALT level (<ULN vs. ULN) 2.2 (1.11–4.34) 
HCV RNA level,  105 IU/ml (8 vs. >8) 4.0 (2.46–6.69) 
Week 4 response (RVR vs. non-RVR) 7.3 (4.52–12.08) 
SVR, sustained virological response; OR, odds ratio; CI, conﬁdence interval; BMI, body ma
hepatitis C virus; RVR, rapid virological response.
a Only covariates signiﬁcantly associated with SVR in the univariable analysis (two-si
model.Factors exhibiting signiﬁcance on univariable logistic regres-
sion analysis were entered into a multivariable logistic regression
analysis to identify independent factors contributing to SVR.
Multivariable analysis showed that age (for 40 vs. >40: OR 4.2,
95% CI 2.30–7.96; p < 0.0001), viral load (for HCV RNA 8  105 IU/
ml vs. >8  105 IU/ml: OR 3.4, 95% CI 1.87–6.25; p < 0.0001), and
RVR at week 4 (for RVR vs. non-RVR: OR 11, 95% CI 6.15–20.69;
p < 0.0001) were signiﬁcantly associated with SVR (Table 3).
3.6. Adverse effects
No serious adverse event was observed. The incidence of non-
serious adverse events related to treatment is shown in Table 4.
The most frequent adverse events were fatigue (in 55.2%),
headache (in 16.2%), and fever (in 12.2%). Fortunately these
symptoms tended to lessen after the ﬁrst few weeks of therapy.
Alopecia was detected in 2.3%, and 10.3% of patients developed a
cough. The most common psychiatric side effect of therapy,
depression, was present in 7.7% of patients. In addition it was noted
that insomnia developed in 7.0% of patients treated with PEG-IFN
a2a plus ribavirin.
4. Discussion
The gold standard treatment for chronic hepatitis C is PEG-IFN
in combination with ribavirin, and the current standard duration of
therapy with this combination for patients infected with HCV
genotype 2 or 3 is 24 weeks.14,15 However the response to antiviral
therapy in HCV-infected patients is heterogeneous. A study by Hu
et al.16 reported that the response to treatment is associated with
viral and host factors. At present there are limited data available on
the efﬁcacy of PEG-IFN a2a plus ribavirin treatment in thearacteristics to predict SVR
onse
Multivariable analysisa
p-Value OR (95% CI) p-Value
0.11 - -
0.005 4.2 (2.30–7.96) <0.0001
0.14 - -
0.02 1.4 (0.68–3.1) 0.37
<0.0001 3.4 (1.87–6.25) <0.0001
<0.0001 11 (6.15–20.69) <0.0001
ss index; ALT, alanine aminotransferase; ULN, upper limit of the normal range; HCV,
ded p-value <0.05) are shown and included in the multivariable logistic regression
Table 4
Adverse effect proﬁle
Adverse events Number %
Fatigue 235 55.2
Headache 69 16.2
Fever 52 12.2
Myalgia 45 10.6
Nausea 23 5.4
Decrease in appetite 53 12.4
Depression 33 7.7
Insomnia 30 7.0
Alopecia 10 2.3
Cough 44 10.3
Leukopeniaa 9 2.1
Anemiab 69 16.2
Thrombocytopeniac 15 3.5
a White blood cells <2.5  109/l.
b Hemoglobin level <10 g/dl.
c Platelets <50  109/l.
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regimen is very expensive and is imposing a huge burden on the
country’s economy because a signiﬁcant proportion of the
Pakistani population (approximately 10 million) is infected with
this virus and most of them are of low economic status.17,18 We
have reported herein the efﬁcacy of this treatment and factors that
will help to predict the response to PEG-IFN a2a plus ribavirin
therapy.
In this study, the overall SVR to PEG-IFN a2a plus ribavirin
therapy was 75.1%. This is comparable to the response rate
predicted by Ascione et al.19 (77.8%), but is high compared to that
reported by Rumi et al.20 (65%). We also identiﬁed viral and host
factors that predict the response to PEG-IFN a2a plus ribavirin
therapy. The most important of these was an RVR. Patients with an
RVR had a signiﬁcantly higher SVR. In the current analysis 74.6% of
patients achieved an RVR and the overall SVR rate was consider-
ably higher in patients who achieved an RVR than in those who did
not achieve an RVR (85.5% vs. 44.4%; p < 0.0001). We also found
RVR to be a signiﬁcant predictor of SVR (OR 11, 95% CI 6.15–20.69;
p < 0.0001). These ﬁndings are supported by those of Puoti et al.,21
who reported an RVR rate of 64% and an SVR rate of 82% in HCV
genotype 3 patients. Therefore RVR is a strong predictor of
treatment success.
The analysis presented here demonstrates no signiﬁcant
difference in virological response to treatment between males
and females (78.5% vs. 71.9%; p = 0.11). However our study
supports the reported observation that the rate of SVR decreases
with increasing age.12,22,23 The SVR rate was highest in patients
aged 40 years (80.8%) and was signiﬁcantly lower in patients
aged >40 years (69.1%). This suggests that the age of the patient
must be considered during treatment recommendation, as a
signiﬁcant difference was found between the different age groups
(Table 3). Moreover older patients (>40 years) who achieved RVR
were more likely to achieve an SVR as compared to patients who
did not achieve RVR (81.1% vs. 7.5%; p < 0.05), indicating that the
impact of RVR on SVR is more pronounced among patients aged
>40 years (as shown in Figure 2).
Xie et al. found viral concentration to be associated with the
balance of replication and clearance of the virus,24 and moreover
that is an indicative of outcome of treatment. Some studies have
demonstrated that a higher baseline viral load is an independent
risk factor for relapse and others have reported a low baseline viral
load as a predictor of achievement of SVR.25,26 However in our
study a clear relationship between baseline viral load and the
response to PEG-IFN a2a plus ribavirin was observed. The SVR rate
was considerably higher in patients with a pre-treatment viral loadof 8  105 IU/ml. The relapse rate increased to 24% in HCV
genotype 3 patients with a viral load >8  105 IU/ml. This ﬁnding is
further veriﬁed by several studies.9,27–29 Multivariable logistic
regression analysis showed that a low baseline viral load was
signiﬁcantly associated with SVR (OR 3.4, 95% CI 1.87–6.25;
p < 0.0001). This result indicates that the baseline level of HCV
RNA predicts the SVR to PEG-IFN plus ribavirin therapy. The
cumulative effect of HCV RNA level and RVR was also studied. An
SVR to PEG-IFN was more common in patients with a high viral
load >8  105 IU/ml if they achieved RVR than in patients with a
high viral load >8  105 IU/ml who did not achieve RVR (79.9% vs.
18.6%; p < 0.05). This shows that patients not achieving RVR and
who have a viral load >8  105 IU/ml are highly unlikely to achieve
an SVR.
Body mass is another factor that might play an important role in
predicting SVR. Rodriguez-Torres et al.30 reported recently that a
patient BMI 27 kg/m2 was associated with an early virological
response. However, we did not ﬁnd a signiﬁcant relationship
between BMI and SVR in the current study.
This was a single-center study involving a relatively high
socioeconomic status group; their adherence to treatment is
higher than for those in lower socioeconomic status groups.
In conclusion, in this prospective analysis we found RVR to be
an independent variable that is predictive of an SVR, along with
pre-treatment HCV-RNA levels and age. Moreover older patients
(>40 years) who achieve an RVR are likely to achieve SVR, while
patients who do not have an RVR and who have a viral load
>8  105 IU/ml are unlikely to have an SVR. These results can be
used to counsel patients on the likelihood of achieving SVR and
may inﬂuence the decisions regarding treatment. These results will
also help to limit the associated adverse events and health care
costs.
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